Home / Science / New ETEC Vaccine Tech Licensed for Development
New ETEC Vaccine Tech Licensed for Development
7 Jul
Summary
- Decades-long research yields ETEC vaccine technology.
- Valneva licenses E. coli tech for further development.
- Potential protection for children against severe diarrhea.
After decades of dedicated research, a significant advancement has been made in the development of a vaccine targeting enterotoxigenic Escherichia coli (ETEC). This bacterium is a primary cause of millions of diarrheal illnesses annually, particularly affecting children in low- and middle-income regions.
The newly developed technology focuses on a key toxin produced by ETEC, which has historically posed a challenge for vaccine creation. Scientists at the University of Bergen and NORCE have pioneered this approach, showing it elicits strong antibody responses that may offer protection.
This promising technology has now been licensed to the French vaccine manufacturer Valneva. While the licensing agreement marks a crucial step, extensive laboratory studies, clinical trials, and regulatory reviews will be necessary before a vaccine becomes available to the public.
Researchers express hope that, if successful, the vaccine could significantly reduce the severity of diarrheal disease in children. Public health experts also advise preventative measures such as practicing good hygiene and consuming safe food and water when traveling to higher-risk areas.
